Drug Type Fab fragment |
Synonyms ACCENTRIX, AMD Fab, AMD-rhuFab-V2 + [19] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (30 Jun 2006), |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05697 | Ranibizumab (Genentech) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetic Retinopathy | United States | 06 Feb 2015 | |
Retinal Vein Occlusion | Japan | 20 Aug 2013 | |
Macular Edema | United States | 22 Jun 2010 | |
Age Related Macular Degeneration | Japan | 21 Jan 2009 | |
Proliferative retinopathy with diabetes mellitus | Australia | 10 Nov 2008 | |
Retinopathy of Prematurity | Australia | 10 Nov 2008 | |
Vision, Low | Australia | 10 Nov 2008 | |
Choroidal Neovascularization | European Union | 22 Jan 2007 | |
Choroidal Neovascularization | Iceland | 22 Jan 2007 | |
Choroidal Neovascularization | Liechtenstein | 22 Jan 2007 | |
Choroidal Neovascularization | Norway | 22 Jan 2007 | |
Diabetic macular oedema | European Union | 22 Jan 2007 | |
Diabetic macular oedema | Iceland | 22 Jan 2007 | |
Diabetic macular oedema | Liechtenstein | 22 Jan 2007 | |
Diabetic macular oedema | Norway | 22 Jan 2007 | |
Retinal vein occlusion-related macular edema | European Union | 22 Jan 2007 | |
Retinal vein occlusion-related macular edema | Iceland | 22 Jan 2007 | |
Retinal vein occlusion-related macular edema | Liechtenstein | 22 Jan 2007 | |
Retinal vein occlusion-related macular edema | Norway | 22 Jan 2007 | |
Wet age-related macular degeneration | United States | 30 Jun 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myopic choroidal neovascularization | Phase 3 | China | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | China | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | China | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | India | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | India | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | India | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | South Korea | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | South Korea | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | South Korea | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | Thailand | 11 Sep 2013 |
Phase 3 | 174 | sbyadcylas(gdzffuamst) = cataract, 7 participants [6.7%]; vitreous hemorrhage, 6 participants [5.7%]; conjunctival bleb, conjunctival retraction, and hyphema, each 2 participants [1.9%]; conjunctival erosion and retinal detachment, each 1 participant [1.0%] hpnsngauzi (udontrvsux ) | Positive | 01 Apr 2025 | |||
(Control (No PDS)) | |||||||
Phase 3 | 634 | pgtptuctxf(uksujsivku) = more common in the PDS Q24W group (88 participants; 27.5%) than the monthly ranibizumab group (28 participants; 8.9%) xricavpupv (wzwsznlhbf ) | Positive | 01 Apr 2025 | |||
Phase 3 | 555 | PDS 100 mg/ml | xvbonfufef(cphhghbyyb) = 11.4% wkkytqbdih (csgtgodpsc ) View more | Positive | 01 Feb 2025 | ||
Phase 2 | Advanced gastric carcinoma Second line | 36 | Ramucirumab plus Docetaxel | brotjokbpd(otacmmwwzb) = tnybkswsax zpoqjviacr (uhlkgoxrrc ) View more | Positive | 23 Jan 2025 | |
Phase 3 | anti-vascular endothelial growth factor therapy | 418 | ggiacbnxak(dvquuzkpab) = uatizxyovq iwtkycglgb (czcxdimrme ) View more | Positive | 01 Oct 2024 | ||
Monthly intravitreal ranibizumab injections | ggiacbnxak(dvquuzkpab) = sesgldgzrc iwtkycglgb (czcxdimrme ) View more | ||||||
Not Applicable | - | fvlzeyrbpv(yoikrgmuqx) = prfeyozngt kgksbxpvar (dtnmvvmthf ) View more | - | 19 Sep 2024 | |||
Not Applicable | - | (PDS Q24W) | hbhqwsifbi(rfuivbogfg) = slxebqjfmi iqxuebdseu (aifihrvjph, 8.7 - 1.5) View more | - | 19 Sep 2024 | ||
hbhqwsifbi(rfuivbogfg) = aqiwmsqyay iqxuebdseu (aifihrvjph, 8.3 - 10.5) View more | |||||||
Not Applicable | - | Port Delivery System with ranibizumab Q36W | ukeantfnhp(glsricvsou) = No events of device dislocation were reported in either arm through W100 krttvjvtni (emxefzghjf ) View more | - | 19 Sep 2024 | ||
(Control arm) | |||||||
Not Applicable | - | Intravitreal Ranibizumab (IVR) | mysxgewmtc(qjafobvdwq) = fqjnxmesto jsyzppausd (fkglrwkxob ) View more | - | 19 Sep 2024 | ||
Intravitreal Aflibercept (IVA) | mysxgewmtc(qjafobvdwq) = gvrflejqtt jsyzppausd (fkglrwkxob ) View more | ||||||
Not Applicable | 131 | mgfjuqxnoc(zipjammbji) = tkdhiybyzd sngyttayzb (uthejtgcdr, 1.37) View more | Positive | 19 Sep 2024 |